The rapid clinical validation of mRNA technology during the COVID‑19 pandemic has powerfully accelerated its application in ...
I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...
The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.
Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.
SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...
The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...
In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls Commercial/Moment via Getty Images Ana Santos Rutschman, Villanova University ...
In December 2025, Moderna submitted an application to the FDA to approve an mRNA flu vaccine for adults age 50 and older. The vaccine had been tested in clinical trials including more than 40,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results